[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201708546UA - Methods for treating lung cancer - Google Patents

Methods for treating lung cancer

Info

Publication number
SG11201708546UA
SG11201708546UA SG11201708546UA SG11201708546UA SG11201708546UA SG 11201708546U A SG11201708546U A SG 11201708546UA SG 11201708546U A SG11201708546U A SG 11201708546UA SG 11201708546U A SG11201708546U A SG 11201708546UA SG 11201708546U A SG11201708546U A SG 11201708546UA
Authority
SG
Singapore
Prior art keywords
methods
lung cancer
treating lung
treating
cancer
Prior art date
Application number
SG11201708546UA
Other languages
English (en)
Inventor
Daniel John O'shannessy
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of SG11201708546UA publication Critical patent/SG11201708546UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201708546UA 2015-04-17 2016-04-14 Methods for treating lung cancer SG11201708546UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562149184P 2015-04-17 2015-04-17
PCT/US2016/027497 WO2016168440A1 (en) 2015-04-17 2016-04-14 Methods for treating lung cancer

Publications (1)

Publication Number Publication Date
SG11201708546UA true SG11201708546UA (en) 2017-11-29

Family

ID=55809240

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201708546UA SG11201708546UA (en) 2015-04-17 2016-04-14 Methods for treating lung cancer

Country Status (13)

Country Link
US (1) US20180125970A1 (he)
EP (1) EP3283886B1 (he)
JP (1) JP2018516244A (he)
KR (1) KR20170137848A (he)
CN (1) CN107624071A (he)
AU (1) AU2016248222A1 (he)
BR (1) BR112017022320A2 (he)
CA (1) CA2983126A1 (he)
IL (1) IL255079A0 (he)
MX (1) MX2017013390A (he)
RU (1) RU2718780C9 (he)
SG (1) SG11201708546UA (he)
WO (1) WO2016168440A1 (he)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116592A2 (en) * 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
TW201625301A (zh) * 2014-06-06 2016-07-16 Kyowa Hakko Kirin Co Ltd 藉由folr1標靶藥及葉酸代謝拮抗劑用於癌症患者之治療方法與醫藥
US10822410B2 (en) 2016-11-23 2020-11-03 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
SG11202007494TA (en) 2018-03-13 2020-09-29 Phanes Therapeutics Inc Anti-folate receptor 1 antibodies and uses thereof
CA3103369A1 (en) * 2018-06-18 2019-12-26 Medimmune Limited Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
CN110221052B (zh) * 2019-06-17 2022-09-23 昆山德诺瑞尔生物科技有限公司 Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用
WO2023170216A1 (en) * 2022-03-11 2023-09-14 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556027C (en) * 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
WO2006116592A2 (en) * 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
MX368394B (es) 2010-11-05 2019-10-01 Eisai Inc Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
SG10201605278PA (en) * 2011-07-15 2016-08-30 Eisai R&D Man Co Ltd Anti-folate receptor alpha antibodies and uses thereof

Also Published As

Publication number Publication date
IL255079A0 (he) 2017-12-31
EP3283886A1 (en) 2018-02-21
RU2718780C2 (ru) 2020-04-14
JP2018516244A (ja) 2018-06-21
MX2017013390A (es) 2018-06-13
RU2718780C9 (ru) 2020-07-08
AU2016248222A1 (en) 2017-11-09
KR20170137848A (ko) 2017-12-13
WO2016168440A1 (en) 2016-10-20
US20180125970A1 (en) 2018-05-10
RU2017136863A3 (he) 2019-08-21
EP3283886B1 (en) 2020-01-15
RU2017136863A (ru) 2019-05-17
CA2983126A1 (en) 2016-10-20
BR112017022320A2 (pt) 2018-07-24
CN107624071A (zh) 2018-01-23

Similar Documents

Publication Publication Date Title
HK1251407A1 (zh) 治療癌症的方法
IL304252A (he) שיטות לטיפול בסרטן
IL289947A (he) שיטה לטיפול בסרטן
ZA201706616B (en) Method for treating cancer
IL255060A0 (he) טיפול משולב לטיפול בסרטן
IL257691A (he) שיטה לטיפול בסרטן
HK1254258A1 (zh) 使用阿吡莫德治療癌症的方法
HK1259342A1 (zh) 用於治療癌症的聯合療法
HK1244217A1 (zh) 用於治療蛋白質病的方法
HK1250944A1 (zh) 用於治療癌症的方法
EP3389634A4 (en) METHOD FOR THE TREATMENT OF CANCER
IL255079A0 (he) שיטות לטיפול בסרטן ריאות
EP3389652A4 (en) METHODS OF TREATING CANCER
HK1248135A1 (zh) 用於治療癌症的聯合方法
IL246558A0 (he) שיטות חדשות לטיפול בסרטן
HK1250942A1 (zh) 用於治療癌症的方法
HK1250943A1 (zh) 用於治療癌症的方法
SG10201508795XA (en) Method for treating cancer
HK1256371A1 (zh) 用於治療腫瘤的方法